|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Drug regimens applied in the year before index hospitalization were as follows: no IBD drugs (43.6% ulcerative colitis, 43.1% Crohn's disease); 5-ASA (45.7% ulcerative colitis, 19.1% Crohn's disease); local steroids (17.9% ulcerative colitis, 17.6% Crohn's disease); systemic steroids (38.6% ulcerative colitis, 29.4% Crohn's disease); immunomodulators (10.7% ulcerative colitis, 18.1% Crohn's disease); biologics (10% ulcerative colitis, 24% Crohn's disease); and calcineurin inhibitors (2.1% ulcerative colitis, 1.5% Crohn's disease).
|
31834046 |
2020 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Areas covered</b>: Several studies demonstrated the ability of 5-ASA to induce endoscopic remission to a similar extent as anti-TNF therapy on the moderate segment of UC.
|
31498003 |
2020 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Costs for CD patients were significantly higher than those for UC regarding all direct expenditures (except for 5-ASA and diagnostic expenses).
|
31076743 |
2020 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This prospective study included 121 UC outpatients treated using 5-ASA tablets.
|
30179881 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The experimental data revealed that the synthesized terpolymeric semi-IPN hydrogel may have useful biomedical applications, especially as a carrier of protein (BSA), or 5-ASA (a therapeutic option for conditions of the colon such as Crohn's Disease and Ulcerative Colitis).
|
30813044 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Related randomized controlled trials (RCTs) that compared one TCM intervention with another or with 5-ASA (placebo) for mild-to-moderate UC from inceptions to February 2019 will be included.
|
31415431 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abbreviations: ADA: Adalimumab; CD: Crohn disease; ECCO: European Crohn's and Colitis Organisation; EEN: exclusive enteral nutrition; ESPGHAN: European Society for Paediatric Gastroenterology Hepatology and Nutrition; FMT: faecal microbiota transplantation; GDP: gross domestic product; HIC: high-income countries; IBD: inflammatory bowel disease; IBDU: inflammatory bowel disease unclassified; IC: ileocolonoscopy; IFX: infliximab; IPAA: ileal pouch anal anastomosis; LMIC: low- and middle-income countries; MH: mucosal healing; OGD: oesophago-gastroduodenoscopy; PCDAI: Paediatric Crohn's Disease Activity Index; PIBD: paediatric inflammatory bowel disease; PUCAI: Paediatric Ulcerative Colitis Activity Index; UC: ulcerative colitis; UGIT: upper gastrointestinal tract; VEO-IBD: very early-onset IBD; WLE: white light endoscopy; 5-ASA: 5 aminosalicylic acid; 6-MP: 6-mercaptopurine.
|
30900526 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to identify predictors of low adherence to oral 5-ASA in Koreans with UC.
|
30901362 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients had mild-to-moderate UC and were undergoing long-term 5-ASA maintenance.
|
30478770 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Kaplan-Meier analysis showed that the event-free survival (exacerbation of disease activity) of UC patients treated with biologics and 5-ASA (n = 42) was not significantly lower than that of those taking biologics alone (n = 21) (log rank test, P = 0.68).
|
31471699 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results from questionnaire survey showed that majority of physicians would prefer oral 5-ASA with topical 5-ASA therapy for distal UC patients.
|
30659678 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program.
|
30963247 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD.
|
30844556 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The subjects were 67 patients with UC who were treated with a pH-dependent or time-dependent formulation of 5-ASA between December 2011 and April 2014.
|
30369547 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only one meta-analysis evaluated clinical remission maintenance, showing no statistically significant difference between MTX and placebo, 5-ASA, or 6-MP in UC.
|
30863001 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focused questions included the following: (1) comparative effectiveness and tolerability of different oral 5-ASA therapies (sulfalsalazine vs diazo-bonded 5-ASAs vs mesalamine; low- (<2 g) vs standard (2-3 g/d) vs high-dose (>3 g/d) mesalamine); (2) comparison of different dosing regimens (once-daily vs multiple times per day dosing) and routes (oral vs rectal vs both oral and rectal); (3) role of oral budesonide in patients mild-moderate UC; (4) comparative effectiveness and tolerability of rectal 5-ASA and corticosteroid formulations in patients with distal colitis; and (5) role of alternative therapies like probiotics, curcumin, and fecal microbiota transplantation in the management of mild-moderate UC.
|
30576642 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
5-ASA may have beneficial effects on the mucosal microbiome, and high concentrations possibly amend dysbiosis in UC.
|
30895635 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increase in the use of topical 5-ASA therapy in UC patients was noted over time from 5% to 38%.
|
28644308 |
2019 |
|
Ulcerative Colitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To explore if mucosal and faecal 5-ASA values correlate with disease activity and/or therapeutic effects in patients with inflammatory bowel disease, especially UC.
|
31013494 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with UC who started anti-TNF after having been on oral 5-ASA for at least 90 days were included.
|
30420398 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common treatments at baseline were biologics (75.3%) and immunosuppressants (70.9%) for CD patients and 5-ASA compounds (77.5%) for UC patients.
|
31636478 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-ASA modifies clinical outcomes among anti-tumor necrosis factor (TNF)-α-treated patients.
|
29925913 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?
|
30060944 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The choice of treatment for refractory UC patients who are allergic to 5-ASA is relatively limited.
|
29742710 |
2018 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a prospective study in adult quiescent UC patients to evaluate the feasibility of spot (Nac-)5-ASA urinalysis by HPLC to assess adherence in daily inflammatory bowel disease (IBD) care.
|
29073323 |
2018 |